Adlai Nortye Ltd.

IPO

Adlai Nortye

Public · Hangzhou, China · Founded 2016 · $253.0M raised

Headquarters
Hangzhou
Founded
2016
Business Model
B2B
Total Funding
$253.0M
Last Round
$100.0M Series DJul 2021
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Adlai Nortye is a global clinical-stage biopharmaceutical company focused on developing differentiated immuno-oncology medicines. Founded in 2016 and headquartered in Hangzhou, China, the company also operates a US headquarters in North Brunswick, New Jersey. Adlai Nortye is listed on Nasdaq under the ticker ANL and is advancing a pipeline of innovative cancer therapies addressing unmet patient needs.

Summary

Adlai Nortye Ltd. is a Biotech company based in Hangzhou, China, founded in 2016. It has raised $253.0M in total across 3 rounds, most recently a $100.0M Series D round in Jul 2021. Investors include Yuanming Capital, Cormorant Asset Management and SDIC Fund Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondary MarketFeb 2026

Sign up to see all 5 events

Funding: Series B through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Adlai Nortye Ltd. on Indexed.vc
<a href="https://indexed.vc/companies/adlai-nortye-ltd"><img src="https://indexed.vc/api/badge/company/adlai-nortye-ltd" alt="Adlai Nortye Ltd. on Indexed.vc" width="260" height="76" /></a>